ezetimibe--simvastatin-drug-combination and Ventricular-Dysfunction--Left

This study sought to assess the impact of valvuloarterial impedance on left ventricular (LV) myocardial systolic function in asymptomatic aortic valve stenosis (AS).. In atherosclerotic AS, LV global load consists of combined valvular and arterial resistance to LV ejection. Global load significantly impacts LV ejection fraction (EF) in symptomatic AS, but less is known about its effect on LV myocardial function in asymptomatic AS.. Echocardiograms in 1,591 patients with asymptomatic AS (67 +/- 10 years, 51% hypertensive) at baseline in the SEAS (Simvastatin Ezetimibe in Aortic Stenosis) study evaluating placebo-controlled combined simvastatin and ezetimibe treatment in AS were used to assess LV global load as valvuloarterial impedance and LV myocardial function as stress-corrected midwall shortening. The study population was divided into tertiles of global load. Stress-corrected midwall shortening was considered low if <87% in men and <90% in women. Low-flow AS was defined as stroke volume index <22 ml/m(2.04).. Energy loss index decreased (0.85 cm(2)/m(2) vs. 0.77 and 0.75 cm(2)/m(2)) and the prevalence of low stress-corrected midwall shortening increased (10% vs. 26% and 63%) with increasing LV global load (all p < 0.001). The EF was low in only 2% of patients. Patients with low-flow AS had higher LV global load and more often low midwall shortening than those with normal-flow AS (9.66 +/- 2.23 mm Hg/ml.m(2.04) and 77%, vs. 6.38 +/- 2.04 mm Hg/ml.m(2.04) and 30%, respectively, p < 0.001). In logistic regression analysis, LV global load was a main predictor of low stress-corrected midwall shortening independent of male sex, concentric LV geometry, LV hypertrophy (all p < 0.001), concomitant hypertension, and aortic regurgitation.. LV global load impacts LV myocardial function in asymptomatic AS independent of other main covariates of LV systolic function. LV myocardial systolic dysfunction is common in asymptomatic AS in particular in patients with low-flow AS and increased valvuloarterial afterload, whereas EF is generally preserved. (An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis [Narrowing of the Major Blood Vessel of the Heart]; NCT00092677).

Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Atherosclerosis; Azetidines; Disease Progression; Double-Blind Method; Drug Combinations; Echocardiography, Doppler; Europe; Ezetimibe, Simvastatin Drug Combination; Female; Hemodynamics; Humans; Hypolipidemic Agents; Logistic Models; Male; Middle Aged; Myocardial Contraction; Predictive Value of Tests; Prospective Studies; Risk Assessment; Risk Factors; ROC Curve; Sensitivity and Specificity; Simvastatin; Systole; Treatment Outcome; United States; Ventricular Dysfunction, Left

Topics: Aortic Valve Stenosis; Atherosclerosis; Azetidines; Calcinosis; Disease Progression; Drug Combinations; Echocardiography, Doppler; Ezetimibe, Simvastatin Drug Combination; Hemodynamics; Humans; Hypolipidemic Agents; Myocardial Contraction; Predictive Value of Tests; Risk Assessment; Risk Factors; Simvastatin; Systole; Treatment Outcome; Ventricular Dysfunction, Left